Cartesian Therapeutics, Inc.
RNAC
$6.49
-$0.17-2.48%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 224.77% | 16.80% | -99.11% | -81.16% | -109.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 224.77% | 16.80% | -99.11% | -81.16% | -109.18% |
| Cost of Revenue | 29.92% | 21.07% | 17.44% | 53.85% | -30.43% |
| Gross Profit | -13.90% | -21.22% | -170.11% | -267.06% | -51.08% |
| SG&A Expenses | 15.66% | 17.59% | 3.03% | -6.05% | -56.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.43% | 19.80% | 12.30% | 25.02% | -43.56% |
| Operating Income | -14.55% | -19.86% | -258.54% | -74.44% | 21.26% |
| Income Before Tax | -921.16% | -48.46% | 14.82% | 68.83% | 94.93% |
| Income Tax Expenses | -3,303.14% | -- | -- | -- | 101.51% |
| Earnings from Continuing Operations | -802.92% | -48.46% | 14.82% | 68.83% | 94.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -802.92% | -48.46% | 14.82% | 68.83% | 94.23% |
| EBIT | -14.55% | -19.86% | -258.54% | -74.44% | 21.26% |
| EBITDA | -14.28% | -18.34% | -252.10% | -67.67% | 22.39% |
| EPS Basic | -782.64% | -22.59% | -11.36% | 94.01% | 99.01% |
| Normalized Basic EPS | -12.26% | -72.73% | -210.22% | 77.43% | 97.82% |
| EPS Diluted | -783.46% | -22.59% | -7.41% | 94.01% | 99.01% |
| Normalized Diluted EPS | -12.26% | -72.73% | -215.22% | 77.43% | 97.82% |
| Average Basic Shares Outstanding | 2.30% | 21.10% | 55.35% | 378.45% | 380.19% |
| Average Diluted Shares Outstanding | 2.30% | 21.10% | 48.65% | 378.45% | 380.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |